Academic Journal
Προβολή σε EDS

Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges.
Συγγραφείς: Jain, Bhawana1,2 (AUTHOR), Sanwaria, Sunita2,3 (AUTHOR), Hadap, Arti2,3,4 (AUTHOR), Joni, I Made2,4,5 (AUTHOR), Febrida, Renny2,5,6 (AUTHOR), Ruslami, Rovina6,7 (AUTHOR), Purnama, Irwan7,8,9 (AUTHOR), Singh, Deoraj8,10 (AUTHOR), Panatarani, Camellia2,5,9 (AUTHOR) c.panatarani@phys.unpad.ac.id
Πηγή: Cancers. Sep2026, Vol. 18 Issue 18, p2982. 34p.
Θεματικοί όροι: *Therapeutic use of biomedical materials, *Glioma treatment, *Gene therapy, *Immunogenetics, *Biotechnology, *Immunotherapy, *Blood-brain barrier, *Cell physiology, *Drug delivery systems, *Drug stability, *Individualized medicine, *Bioavailability, *Nanoparticles, *Phagocytosis
Περίληψη: Simple Summary: Glioblastoma (GBM) is the most aggressive and common brain tumor, highly resistant to conventional treatment, largely due to the blood brain barrier (BBB) limiting effective drug delivery. Biomimetic nanoparticles (BNPs) offer a promising therapeutic approach by mimicking biological structures to improve drug stability, BBB penetration, and tumorspecific targeting while reducing systemic toxicity. BNPs can be engineered from diverse biomaterials, including cell membranes, liposomes, and polymeric systems. Preclinical and early clinical studies show BNPs enhance drug bioavailability and therapeutic efficacy. However, challenges remain stability, immunogenicity, regulatory approval, and scalable production hindering clinical translation. This review highlights recent BNPs advances, targeting strategies, and limitations, while exploring integration with immunotherapy and gene therapy to enable more personalized, effective GBM treatment approaches. Glioblastoma (GBM) is the most aggressive and common type of brain tumor, characterized by rapid growth and infiltration, as well as high resistance to conventional treatments. Given the persistent challenge posed by the bloodbrain barrier (BBB) to effective drug delivery, a shift in therapeutic strategies is required. Biomimetic nanocarriers (BNCs) represent a promising approach for the targeted treatment of malignant brain tumors. By replicating biological structures and functions, BNCs enhance drug stability, facilitate penetration across the BBB, and promote tumor-specific targeting while minimizing the risk of systemic toxicity. These nanocarriers can be engineered using a wide variety of biomaterials, including cell membranes, liposomes, and polymeric systems. Recent preclinical and early clinical studies suggest that BNCs provide a viable method to increase drug bioavailability and therapeutic activity. However, several translational challenges remain, including formulation stability, immunogenicity, regulatory acceptability, and large-scale manufacturing. This review discusses recent advances in BNCs for GBM treatment, drug-targeting strategies, and the structural hurdles that limit their clinical translation. Furthermore, we examine emerging multimodal approaches that integrate BNCs with immunotherapy and gene therapy to enhance personalized GBM treatment. [ABSTRACT FROM AUTHOR]
Βάση Δεδομένων: Academic Search Index
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:asx&genre=article&issn=20726694&ISBN=&volume=18&issue=18&date=20260915&spage=2982&pages=2982-3015&title=Cancers&atitle=Biomimetic%20Nanocarriers%20for%20Glioblastoma%20Therapy%3A%20Translational%20Advances%20and%20Strategic%20Challenges.&aulast=Jain%2C%20Bhawana&id=DOI:10.3390/cancers18182982
    Name: Full Text Finder (for New FTF UI) (ns324271)
    Category: fullText
    Text: Full Text Finder
    MouseOverText: Full Text Finder
Header DbId: asx
DbLabel: Academic Search Index
An: 197384313
RelevancyScore: 1452
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1452.42785644531
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Jain%2C+Bhawana%22">Jain, Bhawana</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sanwaria%2C+Sunita%22">Sanwaria, Sunita</searchLink><relatesTo>2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hadap%2C+Arti%22">Hadap, Arti</searchLink><relatesTo>2,3,4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Joni%2C+I+Made%22">Joni, I Made</searchLink><relatesTo>2,4,5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Febrida%2C+Renny%22">Febrida, Renny</searchLink><relatesTo>2,5,6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ruslami%2C+Rovina%22">Ruslami, Rovina</searchLink><relatesTo>6,7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Purnama%2C+Irwan%22">Purnama, Irwan</searchLink><relatesTo>7,8,9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Singh%2C+Deoraj%22">Singh, Deoraj</searchLink><relatesTo>8,10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Panatarani%2C+Camellia%22">Panatarani, Camellia</searchLink><relatesTo>2,5,9</relatesTo> (AUTHOR)<i> c.panatarani@phys.unpad.ac.id</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Cancers%22">Cancers</searchLink>. Sep2026, Vol. 18 Issue 18, p2982. 34p.
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: *<searchLink fieldCode="DE" term="%22Therapeutic+use+of+biomedical+materials%22">Therapeutic use of biomedical materials</searchLink><br />*<searchLink fieldCode="DE" term="%22Glioma+treatment%22">Glioma treatment</searchLink><br />*<searchLink fieldCode="DE" term="%22Gene+therapy%22">Gene therapy</searchLink><br />*<searchLink fieldCode="DE" term="%22Immunogenetics%22">Immunogenetics</searchLink><br />*<searchLink fieldCode="DE" term="%22Biotechnology%22">Biotechnology</searchLink><br />*<searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br />*<searchLink fieldCode="DE" term="%22Blood-brain+barrier%22">Blood-brain barrier</searchLink><br />*<searchLink fieldCode="DE" term="%22Cell+physiology%22">Cell physiology</searchLink><br />*<searchLink fieldCode="DE" term="%22Drug+delivery+systems%22">Drug delivery systems</searchLink><br />*<searchLink fieldCode="DE" term="%22Drug+stability%22">Drug stability</searchLink><br />*<searchLink fieldCode="DE" term="%22Individualized+medicine%22">Individualized medicine</searchLink><br />*<searchLink fieldCode="DE" term="%22Bioavailability%22">Bioavailability</searchLink><br />*<searchLink fieldCode="DE" term="%22Nanoparticles%22">Nanoparticles</searchLink><br />*<searchLink fieldCode="DE" term="%22Phagocytosis%22">Phagocytosis</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Simple Summary: Glioblastoma (GBM) is the most aggressive and common brain tumor, highly resistant to conventional treatment, largely due to the blood brain barrier (BBB) limiting effective drug delivery. Biomimetic nanoparticles (BNPs) offer a promising therapeutic approach by mimicking biological structures to improve drug stability, BBB penetration, and tumorspecific targeting while reducing systemic toxicity. BNPs can be engineered from diverse biomaterials, including cell membranes, liposomes, and polymeric systems. Preclinical and early clinical studies show BNPs enhance drug bioavailability and therapeutic efficacy. However, challenges remain stability, immunogenicity, regulatory approval, and scalable production hindering clinical translation. This review highlights recent BNPs advances, targeting strategies, and limitations, while exploring integration with immunotherapy and gene therapy to enable more personalized, effective GBM treatment approaches. Glioblastoma (GBM) is the most aggressive and common type of brain tumor, characterized by rapid growth and infiltration, as well as high resistance to conventional treatments. Given the persistent challenge posed by the bloodbrain barrier (BBB) to effective drug delivery, a shift in therapeutic strategies is required. Biomimetic nanocarriers (BNCs) represent a promising approach for the targeted treatment of malignant brain tumors. By replicating biological structures and functions, BNCs enhance drug stability, facilitate penetration across the BBB, and promote tumor-specific targeting while minimizing the risk of systemic toxicity. These nanocarriers can be engineered using a wide variety of biomaterials, including cell membranes, liposomes, and polymeric systems. Recent preclinical and early clinical studies suggest that BNCs provide a viable method to increase drug bioavailability and therapeutic activity. However, several translational challenges remain, including formulation stability, immunogenicity, regulatory acceptability, and large-scale manufacturing. This review discusses recent advances in BNCs for GBM treatment, drug-targeting strategies, and the structural hurdles that limit their clinical translation. Furthermore, we examine emerging multimodal approaches that integrate BNCs with immunotherapy and gene therapy to enhance personalized GBM treatment. [ABSTRACT FROM AUTHOR]
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asx&AN=197384313
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/cancers18182982
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 34
        StartPage: 2982
    Subjects:
      – SubjectFull: Therapeutic use of biomedical materials
        Type: general
      – SubjectFull: Glioma treatment
        Type: general
      – SubjectFull: Gene therapy
        Type: general
      – SubjectFull: Immunogenetics
        Type: general
      – SubjectFull: Biotechnology
        Type: general
      – SubjectFull: Immunotherapy
        Type: general
      – SubjectFull: Blood-brain barrier
        Type: general
      – SubjectFull: Cell physiology
        Type: general
      – SubjectFull: Drug delivery systems
        Type: general
      – SubjectFull: Drug stability
        Type: general
      – SubjectFull: Individualized medicine
        Type: general
      – SubjectFull: Bioavailability
        Type: general
      – SubjectFull: Nanoparticles
        Type: general
      – SubjectFull: Phagocytosis
        Type: general
    Titles:
      – TitleFull: Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jain, Bhawana
      – PersonEntity:
          Name:
            NameFull: Sanwaria, Sunita
      – PersonEntity:
          Name:
            NameFull: Hadap, Arti
      – PersonEntity:
          Name:
            NameFull: Joni, I Made
      – PersonEntity:
          Name:
            NameFull: Febrida, Renny
      – PersonEntity:
          Name:
            NameFull: Ruslami, Rovina
      – PersonEntity:
          Name:
            NameFull: Purnama, Irwan
      – PersonEntity:
          Name:
            NameFull: Singh, Deoraj
      – PersonEntity:
          Name:
            NameFull: Panatarani, Camellia
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 09
              Text: Sep2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 20726694
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 18
          Titles:
            – TitleFull: Cancers
              Type: main
ResultId 1